Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma

被引：5

作者：

Sun Fu-kang ^{[1
]}

He Hong-chao ^{[1
]}

Su Ting-wei ^{[2
]}

Zhou Wen-long ^{[1
]}

Huang Xin ^{[1
]}

Dai Jun ^{[1
]}

Shen Zhou-jun ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Urol, Shanghai 200025, Peoples R China

[2] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Endocrinol,Clin Ctr Shanghai Endocrine & Met, Shanghai 200025, Peoples R China

来源：

CHINESE MEDICAL JOURNAL | 2012年 / 125卷 / 12期

关键词：

sunitinib; targeted therapy; anti-angiogenesis; malignant pheochromocytoma; EFFICACY;

D O I：

10.3760/cma.j.issn.0366-6999.2012.12.027

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sporadic malignant pheochromocytoma, a rare disease with poor prognosis, is always difficult to treat due in part to lack of effective agents. We presented three patients with advanced malignant pheochromocytoma treated by sunitinib, which indicates that sunitinib is an effective agent for this malignancy.

引用

页码：2231 / 2234

页数：4

共 50 条

[31] MEDI 301-ABT-869, an orally active multi-targeted receptor tyrosine kinase inhibitor
Dai, Yujia
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
[32] A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia
Fathi, Amir T.
Blonquist, Traci M.
Levis, Mark J.
Hernandez, Daniela
Ballen, Karen K.
Avigan, David E.
Joyce, Robin
McMasters, Malgorzata
Logan, Emma
Hobbs, Gabriela S.
Brunner, Andrew M.
Connolly, Christine
Perry, Ashley M.
Joseph, Christelle
Som, Tina T.
Ramos, Aura Y.
Neuberg, Donna S.
Amrein, Philip C.
BLOOD, 2016, 128 (22)
[33] Multi-targeted tyrosine kinase inhibitor Cabozantinib as a therapeutic agent in MET-overexpressing gastric cancer
Choi, Audrey H.
Lu, Jianming
Lee, Sangjun
Chu, Peiguo
Chung, Vincent
Lin, Ren-Jang
Kim, Joseph
Chao, Joseph
CANCER RESEARCH, 2015, 75
[34] A phase II study of sunitinib, an oral multi-targeted tyrosine kinase inhibitor, in patients with unresectable, locally advanced or metastatic cervical carcinoma: IND184
Mackay, H.
Tinker, A.
Winquist, E.
Thomas, G.
Sederias, J.
Ivy, P.
Eisenhauer, E. A.
EJC SUPPLEMENTS, 2008, 6 (12): : 66 - 66
[35] Multi-targeted tyrosine kinase inhibitors and VEGFR-targeting agents
Eckhardt, SG
ANNALS OF ONCOLOGY, 2006, 17 : 20 - 20
[36] Preclinical development of a novel multi-targeted kinase inhibitor, MG516, for the treatment of sarcoma
Ivy, Kathryn S.
Patwardhan, Parag P.
Schwartz, Gary K.
CANCER RESEARCH, 2014, 74 (19)
[37] Profound Hair and Skin Hypopigmentation in an African American Woman Treated With the Multi-Targeted Tyrosine Kinase Inhibitor Pazopanib
Sideras, Kostandinos
Menefee, Michael E.
Burton, Jill K.
Erlichman, Charles
Bible, Keith C.
Ivy, S. Percy
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) : E312 - E313
[38] Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects
Bello, Carlo L.
Sherman, Laurie
Zhou, Jihao
Verkh, Lev
Smeraglia, John
Mount, Janessa
Klamerus, Karen J.
ANTI-CANCER DRUGS, 2006, 17 (03) : 353 - 358
[39] A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy
Ross, Brian D.
Jang, Youngsoon
Welton, Amanda
Bonham, Christopher A.
Palagama, Dilrukshika S. W.
Heist, Kevin
Boppisetti, Jagadish
Imaduwage, Kasun P.
Robison, Tanner
King, Leah R.
Zhang, Edward Z.
Amirfazli, Cyrus
Luker, Kathryn E.
Lee, Winston Y.
Luker, Gary D.
Chenevert, Thomas L.
Van Dort, Marcian E.
NATURE COMMUNICATIONS, 2022, 13 (01)
[40] The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication
Martin Michaelis
Christina Paulus
Nadine Löschmann
Stephanie Dauth
Elisabeth Stange
Hans Wilhelm Doerr
Michael Nevels
Jindrich Cinatl
Cellular and Molecular Life Sciences, 2011, 68 : 1079 - 1090

← 1 2 3 4 5 →